A Study to Test Whether BI 765845 Helps People Who Have Had an Acute Heart Attack - Trial NCT06139328
Access comprehensive clinical trial information for NCT06139328 through Pure Global AI's free database. This Phase 2 trial is sponsored by Boehringer Ingelheim and is currently Not yet recruiting. The study focuses on Myocardial Infarction. Target enrollment is 350 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Boehringer Ingelheim
Timeline & Enrollment
Phase 2
Nov 16, 2023
Mar 15, 2027
Primary Outcome
Infarct severity
Summary
This study is open to adults aged 18 and over who have just had a heart attack. The purpose
 of this study is to find out whether a medicine called BI 765845 helps people who have had a
 heart attack. The investigators also want to test how well different doses of BI 765845 work
 and how they are tolerated by people who have had a heart attack.
 
 Participants are randomly assigned to receive either BI 765845 or placebo. Placebo treatments
 look like BI 765845 treatments but do not contain any medicine. Participants are about 4
 times as likely to receive BI 765845 than placebo.
 
 Participants are in the study for 3 months. During this time, they visit the study site 7
 times and get 3 phone calls from the site staff. At the visits, the doctors use clinical
 tests to check the health of the heart. The results are compared between the BI 765845 and
 placebo groups to see whether the treatment works. The doctors also regularly check
 participants 'health and take note of any unwanted effects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06139328
Non-Device Trial